Can Atrium Therapeutics' $15 Million Milestone From Bristol Myers Squibb Validate Its RNA Platform?
The pharmaceutical industry's latest milestone payment, a $15 million windfall from Bristol Myers Squibb Company (NYSE:BMY) for delivering a lead RNA compound targeting an undisclosed cardiology indication, has sparked debate about the validity of Atrium Therapeutics, Inc.
's (NASDAQ:RNA) RNA platform. This payment is part of a global collaboration with Bristol Myers that could yield up to $1.